HK010, a novel anti-PDL1 x CD137 bispecific antibody, exhibits potent anti-tumor immunity and low toxicity

被引：0
|
作者：
Li, Liangwei
Liu, Wenting
Shen, Guodong
Zhang, Dayan
Zhou, Weiming
Wang, Fengrong
Zeng, Xiaoli
Huang, Yang
Cheng, Liansheng
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2023-5657
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5657
引用
收藏
页数：2
相关论文
共 50 条
  • [1] A novel anti-PDL1 x anti-VEGFR2 bispecific antibody for enhanced antitumor immunity
    Lu, Dan
    Polonskaya, Zhanna
    Zhang, Haifan
    Luna, Xenia
    Martomo, Stella
    Zhang, Zhikai
    Zhong, Zhaojing
    Wu, Yan
    Patel, Jeegar
    Tonra, James
    Witte, Larry
    Waksal, Sam
    Zhu, Zhenping
    CANCER RESEARCH, 2016, 76
  • [2] A novel anti-CD137 antibody recognizing the membrane-proximal CD137 domain elicits potent anti-tumor T cell activity in a bispecific antibody format.
    Lee, Yangsoon
    Lee, Suyoun
    Kim, Yeunju
    Chung, Hyejin
    Park, Kyungjin
    Park, Eunyoung
    Park, Kyeong-Su
    Jung, Jinwon
    Sung, Byungje
    Won, Jonghwa
    CANCER RESEARCH, 2021, 81 (13)
  • [3] A novel anti-LAG-3/TIGIT bispecific antibody exhibits potent anti-tumor efficacy in mouse models as monotherapy or in combination with PD-1 antibody
    Dai, Tongcheng
    Sun, Hao
    Liban, Tyler
    Vicente-Suarez, Ildefonso
    Zhang, Bin
    Song, Yongping
    Jiang, Zhongxing
    Yu, Jifeng
    Sheng, Jackie
    Lv, Binhua
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [4] A human CD137×PD-L1 bispecific antibody promotes anti-tumor immunity via context-dependent T cell costimulation and checkpoint blockade
    Cecile Geuijen
    Paul Tacken
    Liang-Chuan Wang
    Rinse Klooster
    Pieter Fokko van Loo
    Jing Zhou
    Arpita Mondal
    Yao-bin Liu
    Arjen Kramer
    Thomas Condamine
    Alla Volgina
    Linda J. A. Hendriks
    Hans van der Maaden
    Eric Rovers
    Steef Engels
    Floris Fransen
    Renate den Blanken-Smit
    Vanessa Zondag-van der Zande
    Abdul Basmeleh
    Willem Bartelink
    Ashwini Kulkarni
    Wilfred Marissen
    Cheng-Yen Huang
    Leslie Hall
    Shane Harvey
    Soyeon Kim
    Marina Martinez
    Shaun O’Brien
    Edmund Moon
    Steven Albelda
    Chrysi Kanellopoulou
    Shaun Stewart
    Horacio Nastri
    Alexander B. H. Bakker
    Peggy Scherle
    Ton Logtenberg
    Gregory Hollis
    John de Kruif
    Reid Huber
    Patrick A. Mayes
    Mark Throsby
    Nature Communications, 12
  • [5] Induction of anti-tumor immunity by concomitant cell therapy and trifunctional bispecific antibody anti-(CD3 x Anti-EpCAM)
    Slavin, Shimon
    Lindhofer, Horst
    Yacovlev, Elena
    Gelfand, Yael
    Morecki, Shoshana
    JOURNAL OF IMMUNOTHERAPY, 2006, 29 (06) : 676 - 676
  • [6] DXC025, a novel anti-MUC1/EGFR bispecific antibody-tubulysin conjugate with a function linker, exhibits potent anti-tumor efficacy
    Jiang, Xingyan
    Jia, Junxiang
    Guo, Huihui
    Kong, Xiangfei
    Xu, Yongfang
    Ye, Sishi
    Du, Yong
    Ye, Zhicang
    Cen, Qikuang
    Zhang, Lingli
    Chen, Yongxiang
    Chen, Gaituo
    Bai, Lu
    Zheng, Yunxia
    Zheng, Wei
    Zheng, Jun
    Wang, Juan
    Li, Wenjun
    Huang, Yuanyuan
    Zhao, Linyao
    Xu, Yifang
    Liu, Mengmeng
    Chen, Binbin
    Dai, Meng
    Chen, Miaomiao
    Guo, Zhixiang
    Yang, Qingliang
    Zhao, Robert Y.
    CANCER RESEARCH, 2024, 84 (06)
  • [7] PT217, an anti-DLL3/anti-CD47 bispecific antibody, exhibits anti-tumor activity through novel mechanisms of action
    Jia, Haiqun
    Fang, Dorthy
    Lobsinger, Molly
    Long, Yan
    Chen, Kelan
    Lam, Albert
    Guo, Yangyang
    Selesniemi, Kaisa
    Wang, Ming
    Zou, Hui
    CANCER RESEARCH, 2022, 82 (12)
  • [8] Irinotecan Augmented Anti-Tumor Activity of Anti-PDL1 through Enhancing CD8 Proliferation Regardless of Its Hematotoxicity
    Iwai, T.
    Sugimoto, M.
    Wakita, D.
    Yorozu, K.
    Kurasawa, M.
    Yamamoto, K.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2417 - S2418
  • [9] Potent anti-tumor activity of AbGn-100, an anti-CD326 x anti-TCR bispecific antibody to CD326-expressing solid tumors
    Chiang, Evelyn
    Lee, Shu-Hua
    Tsai, Yu-Ying
    Liu, Meng-Ru
    Hsieh, Yu-Chi
    Huang, Chiu-Chen
    Lin, Shih-Yao
    CANCER RESEARCH, 2012, 72
  • [10] Anti-tumor immunity of M9657, a conditional CD137 immune agonist, is correlated with mesothelin expression on tumor cells
    Xu, Chunxiao
    Zhou, Xueyuan
    Yalavarthi, Sireesha
    Schweickhardt, Rene
    Blaukat, Andree
    Helming, Laura
    CANCER RESEARCH, 2023, 83 (07)
12345